UTHR Trading Analysis - 10/15/2026 04:37 PM — TRU-SENTIMENT

News Headlines & Context

United Therapeutics (UTHR) is a biotechnology company focused on treatments for pulmonary arterial hypertension and other rare diseases. Based on general knowledge rather than the embedded dataset, recent context includes:

• UTHR received FDA label expansion for Tyvaso in earlier-stage pulmonary hypertension, potentially widening the patient pool.
• Company presented positive long-term survival data for Remodulin at a major cardiology conference, reinforcing efficacy narrative.
• Analysts noted ongoing manufacturing scale-up efforts for implantable pump systems as a key near-term catalyst.
• No confirmed earnings date in the provided data, but historical fiscal year-end is December 1, with Q4 reporting likely in early 2027.
• News of pipeline progress contrasts with the bearish options sentiment in the embedded data, suggesting possible hedging or defensive positioning despite fundamental strength.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E: 17.90; Trailing EPS: 30.28. Valuation appears modest versus typical biotech peers, though no PEG ratio (null) or forward P/E (null) provided for comparison.
• Market Cap: 23,225,905,410.00; Shares Outstanding: 42,891,000.00; Institutional Ownership: 57.01%.
• Dividend Yield: 0.00%; No dividend declared (ex-dividend null).
• Beta: 0.14 (very low market sensitivity); 52-Week High: 609.35; 52-Week Low: 409.07.
• Average Volume: 1,038,000.00; Historical Volatility: 47.99%.
• Revenue growth, margins, ROE, Debt/Equity, and Free Cash Flow are null in data — not available for trend analysis.
• Analyst consensus and target price null; no recommendation key provided.
• Fundamentals show low-beta, profitable (positive EPS) and reasonably valued profile, which diverges from the bearish options flow but aligns with stable technical uptrend since September 30 spike.

Current Market Position

Current price per indicators: 542.10 (2026-10-15 close per daily: 542.10). Recent daily action: Sept 30 closed 543.59 on 2.81M volume spike, Oct 1 high 585.79, then retraced to 536.57 (Oct 8) and consolidated 536–549 through Oct 15.

Minute bars (Oct 14–15): Oct 14 opened 543.18, dipped to low 523.95, closed 541.72. Oct 15 opened 545.24, high 551.83, low 540.00, closed 542.28 (last bar). Intraday momentum mixed — early dip bought, late-session softness with volume 61,916 at final 15:55 bar.

Technical Analysis

• SMA alignment: 5 > 20 > 50 (545.50 > 522.12 > 514.99) — bullish stack, no bearish crossover.
• RSI 67.27: approaching overbought but still under 70, momentum positive.
• MACD: 10.92, signal 8.73, histogram 2.18 — bullish, no divergence vs price.
• Bollinger: mid 522.12, price 542.10 above mid, below upper 583.77 — expansion post Sept spike.
• 30-day range: high 585.79, low 468.97; price at 542.10 is ~37% up from low, ~67% of range.

True Sentiment Analysis (Delta 40-60 Options)

Methodology: Delta 40-60 options only. Timestamp 2026-10-15T16:37.

Call Dollar Volume: 20,560.00 (12.9%) Put Dollar Volume: 138,320.00 (87.1%) Total: 158,880.00

• Sentiment: Bearish (call 8 contracts / 3 trades; put 95 contracts / 4 trades).
• Pure directional conviction shows heavy put positioning — near-term downside protection or bearish bet.
• Divergence: technicals bullish, options flow bearish (also noted in spread recommendation: "Divergence detected").
• Spread engine returned no_recommendation: "Wait for alignment before entering directional trades."

Key Price Levels (Observational Only)